Literature DB >> 19569052

GLUT-1 expression and response to chemoradiotherapy in rectal cancer.

Sarah Brophy1, Katherine M Sheehan, Deborah A McNamara, Joseph Deasy, David J Bouchier-Hayes, Elaine W Kay.   

Abstract

Preoperative chemoradiotherapy is used in locally advanced rectal cancer to reduce local recurrence and improve operability, however a proportion of tumors do not undergo significant regression. Identification of predictive markers of response to chemoradiotherapy would improve patient selection and may allow response modification by targeting of specific pathways. The aim of this study was to determine whether expression of glucose transporter-1 (GLUT-1) and p53 in pretreatment rectal cancer biopsies was predictive of tumor response to chemoradiotherapy. Immunohistochemical staining for GLUT-1 and p53 was performed on 69 pretreatment biopsies and compared to tumor response in the resected specimen as determined by the tumor regression grade (TRG) scoring system. GLUT-1 expression was significantly associated with reduced response to chemoradiotherapy and increasing GLUT expression correlated with poorer response (p=0.02). GLUT-1 negative tumors had a 70% probability of good response (TRG3/4) compared to a 31% probability of good response in GLUT-1 positive tumors. GLUT-1 may be a useful predictive marker of response to chemoradiotherapy in rectal cancer. Copyright (c) 2009 UICC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19569052     DOI: 10.1002/ijc.24693

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy.

Authors:  Susumu Saigusa; Yuji Toiyama; Koji Tanaka; Yoshinaga Okugawa; Hiroyuki Fujikawa; Kohei Matsushita; Keiichi Uchida; Yasuhiro Inoue; Masato Kusunoki
Journal:  Surg Today       Date:  2011-11-11       Impact factor: 2.549

2.  Scoring of prognostic parameters in patients with unresectable advanced or recurrent colorectal cancer undergoing chemotherapy.

Authors:  Masahide Ikeguchi; Ryugo Shimoda; Manabu Yamamoto; Yoshihiko Maeta; Keigo Ashida; Hiroaki Saito
Journal:  Yonago Acta Med       Date:  2013-09-11       Impact factor: 1.641

3.  Gender-related differences in pathological and clinical tumor response based on immunohistochemical proteins expression in rectal cancer patients treated with short course of preoperative radiotherapy.

Authors:  Anna Gasinska; Agnieszka Adamczyk; Joanna Niemiec; Beata Biesaga; Zbigniew Darasz; Jan Skolyszewski
Journal:  J Gastrointest Surg       Date:  2014-04-23       Impact factor: 3.452

4.  Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy.

Authors:  Itaru Chiba; Kazuhiko Ogawa; Takamitsu Morioka; Hideaki Shimoji; Nao Sunagawa; Shiro Iraha; Tadashi Nishimaki; Naomi Yoshimi; Sadayuki Murayama
Journal:  Oncol Lett       Date:  2010-10-27       Impact factor: 2.967

5.  Glucose conjugation for the specific targeting and treatment of cancer.

Authors:  Emilia C Calvaresi; Paul J Hergenrother
Journal:  Chem Sci       Date:  2013-06       Impact factor: 9.825

Review 6.  The Potential Role of Changes in the Glucose and Lipid Metabolic Pathways in Gastrointestinal Cancer Progression: Strategy in Cancer Therapy.

Authors:  Gordon A Ferns; Milad Shahini Shams Abadi; Ahmad Raeisi; Mohammad-Hassan Arjmand
Journal:  Gastrointest Tumors       Date:  2021-08-05

7.  Expression and clinical significance of glucose transporter-1 in pancreatic cancer.

Authors:  Kai Lu; Jian Yang; DE-Chun Li; Song-Bing He; Dong-Ming Zhu; Li-Feng Zhang; X U Zhang; Xiao-Chen Chen; Bing Zhang; Jian Zhou
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

8.  A promising independent prognostic biomarker in colorectal cancer: P2X7 receptor.

Authors:  Ilknur Calik; Muhammet Calik; Gulistan Turken; Ibrahim Hanifi Ozercan
Journal:  Int J Clin Exp Pathol       Date:  2020-02-01

9.  Progress in rectal cancer treatment.

Authors:  Wim P Ceelen
Journal:  ISRN Gastroenterol       Date:  2012-08-30

10.  Emerging glycolysis targeting and drug discovery from chinese medicine in cancer therapy.

Authors:  Zhiyu Wang; Neng Wang; Jianping Chen; Jiangang Shen
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-12       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.